Document:

Exhibit 10.1

 

ELECTION TO EXERCISE WARRANTS

	 	 
	 	
         

        October 31, 2014

         

        DelMar Pharmaceuticals, Inc.

        Suite 720 - 999 West Broadway

        Vancouver, British Columbia CANADA V5Z 1K5

	 	
        Attn: Corporate Secretary

        Fax. No. 604.608.5685

Reference is made to the Warrant
to purchase __________________shares of the Common Stock of DelMar Pharmaceuticals, Inc. which was issued to me on ________________
(the “Investor Warrant”). I hereby agree and elect to exercise for cash as set forth below some or all of all of the
Investor Warrants at the reduced exercise price of $0.65 per share as set forth in Table 1 below. The securities being offered
pursuant to this Election to Exercise Warrants are being offered pursuant to exemptions provided by Section 4(2) of the Securities
Act of 1933, as amended and Regulation D thereunder.

TABLE 1

NUMBER OF INVESTOR WARRANTS TO BE
EXERCISED

 

	 	 	 
	A	 	B
	Number of “Investor Warrants” Being Exercised:  	 	
        Exercise Price Per Share

         

	
        _____________________________________

         
	 	$0.65

EXERCISE PRICE AND STOCK CERTIFICATES

The undersigned hereby irrevocably
elects to exercise and to purchase the number of shares of DelMar Pharmaceuticals, Inc. common stock issuable upon exercise of
Investor Warrants listed in Table 1 above and delivery of:

$_________________ (in cash, which
is the product of $.65 per share multiplied by the number of Investor Warrants being exercised hereunder as set forth in Table
1 above).

The undersigned requests that certificates
for such shares be issued in the name of:

 

________________________________________________________________________

(Please print
name, address and social security or federal employer

identification number (if applicable))

 

 If the shares issuable upon this
exercise are not all of the shares issuable for all of the holder’s Investor Warrants, the undersigned requests that a new
Warrant evidencing the rights not so exercised (which Investor Warrants shall continue to have an exercise price of $0.80 per share)
be issued in the name of and delivered to:

 

________________________________________________________________

(Please print name, address and
social security or federal employer

identification number (if applicable))

 

	 
	Name of Holder (print):___________________________________
	
         

        Signature:_____________________________________________
        

	
         

        Title:_________________________________________________

	
         

        Dated:________________________________________________

         

         

    	1

    	 

    

ACKNOWLEDGMENTS AND REPRESENTATIONS
AND WARRANTIES

I understand and acknowledge that:

(1) To exercise
the Investor Warrants at the reduced exercise price of $.65 per share, I must comply with the “Instructions for Delivery”
(attached hereto).

(2) I hereby
agree and acknowledge that upon the Company’s acceptance of this Election to Exercise Warrants as evidenced by the Company’s
acknowledging and returning a countersigned copy of this Election to Exercise Warrants my Investor Warrants described in Table
1 above shall be deemed automatically amended as applicable to give effect to the exercise of the Investor Warrants pursuant to
this Election to Exercise Warrants, without any further action or signature required by me or the Company. Until the acceptance
by the Company of the payment for the exercise price for the Investor Warrant being exercised, such funds will be placed into a
separate non-interest bearing account until the earlier of acceptance of this Election to Exercise Warrants or October 30, 2014
(the “Expiration Date”). If the Company has not accepted this Election to Exercise Warrants by the Expiration Date,
it shall return the proceeds for the exercise price of the Investor Warrants to the holder of such Warrant.

(3) I understand
that by executing this Election to Exercise Warrants, I am automatically, irrevocably and contemporaneously exercising my Investor
Warrants and thereafter such Investor Warrants will be null and void.

(4) If I have
decided to exercise less than my total number of Investor Warrants, the Company will send me a new Investor Warrant which shall
be on the same form, including the original exercise price, as the original Investor Warrants issued to me in connection with the
private offering (the “Private Placement”) of Common Stock pursuant to the certain Private Placement Memorandum dated
January 4, 2013 for the amount of Investor Warrants I excluded from this Election to Exercise Warrants.

(5) The Company
has advised me to consult with my own legal, tax and accounting advisors as to the consequences of exercising my Investor Warrants.

(6) I have
accurately completed and executed the Accredited Investor Questionnaire and understand that the Company will not accept any Election
to Exercise Warrants from or on behalf of any Investor Warrant holders if the Company determines that a valid securities exception
is not available for the exercise of the Investor Warrants at the reduced exercise price under the Securities Act of 1933, as amended.

(7) All authority
herein conferred or agreed to be conferred shall not be affected by, and shall survive, my death or incapacity, and all of my obligations
hereunder shall be binding upon my heirs, personal representatives, successors and assigns and my election to exercise my Investor
Warrants is irrevocable.

(8) Upon request,
I will execute and deliver any additional documents deemed by the Company to be necessary or desirable to complete the amendment
and exercise of the Investor Warrants pursuant to this Election to Exercise Warrants.

(9) I acknowledge
that neither the Securities Exchange Commission nor any state securities commission has approved or disapproved of the transactions
contemplated herein, passed up on the merits or fairness of the transaction; or passed upon the adequacy or accuracy of the disclosure
in this document.

(10) I acknowledge
that the Investor Warrants and the shares of common stock issuable upon exercise of the Investor Warrants, as amended hereby, are
“restricted securities” and may not be sold by the holder absent a registration statement covering the resale of the
shares or an exemption from the registration requirement. I further acknowledge that there is no established trading marked for
the Investor Warrants and we do not intend to list the Investor Warrants for trading on any exchange or market.

I hereby represent
and warrant that:

(1) I have
the full power and authority to execute, deliver and perform any obligations hereunder and that, when and to the extent the Investor
Warrants are accepted for exercise by the Company, the Investor Warrants will be free and clear of all security interests, liens,
restrictions, charges, encumbrances, conditional sales agreements or other obligations relating to the sale or transfer thereof
and the Investor Warrants will not be subject to any adverse claims.

    	2

    	 

    

(2) I either
alone or with my purchaser representative have such knowledge and experience in financial and business matters that I am capable
of evaluating the merits and risks of investment in the warrants shares issuable upon the exercise of the Investor Warrants.

(3) I have
had the opportunity to review the current business prospects, financial condition and operating history of the Company as set forth
in the filings that the Company has made with the Securities and Exchange Commission, including, but not limited to, the Company’s
Annual Report on form 10-K for the year ended December 31, 2013 and the Company’s Report on form 10-KT for the period ended
June 30, 2014; and

(4) I have
had the opportunity to ask questions and receive answers from the Company regarding the terms and conditions pertaining to my execution
of this Election to Exercise Warrants and I have received all the information I consider necessary or appropriate for deciding
whether to exercise my Investor Warrant.

[REMAINDER OF THIS PAGE INTENTIONALLY
LEFT BLANK]

 

    	3

    	 

    

If you
execute the election above to exercise your Investor Warrants and return this signature page, your Investor Warrants will be deemed
amended and exercised in accordance with the terms and conditions of the this Election to Exercise Warrants. Any portion of the
Investor Warrants that are not exercised shall continue to be exercisable upon the terms and conditions, including the exercise
price, of the original Investor Warrants issued to the undersigned holder in connection with the Private Placement. 

You must
complete and sign the following exactly as your name appears on your Investor Warrants. If the signature is by a trustee, executor,
administrator, guardian, attorney-in-fact or another person acting in a fiduciary or representative capacity, please set forth
the signatory’s full title and include with this Election to Participate and Exercise Warrants proper evidence of the authority
of such person to act in such capacity.

 

	Date: October 31, 2014	By:	 
	 	Signature	 
	 	 	 
	 	 	 
	 	(Print name):	 
	 	 	 
	 	(Title, if applicable)	 
	 	 	 
	 	Address:	 
	 	 	 
	 	Telephone:	 
	 	 	 
	 	Fax:	 
	 	 	 
	 	Tax ID/SSN:	 

 

AGREED AND ACCEPTED:

 

 

DelMar Pharmaceuticals, Inc. 

 

 

By:_________________________

Jeffrey Bacha

President and CEO

 

    	4

    	 

    

 

INSTRUCTIONS FOR DELIVERY

To affect your acceptance of the
Election to Warrants you must:

 

	 	(1)	Complete, sign and return this Election to Exercise Warrants.

 

	 	(2)	Tender your Investor Warrants for each Investor Warrant to be exercised.

 

	 	(3)	Complete, sign and return the Accredited Investor Questionnaire (attached hereto).

 

	 	(4)	Pay the exercise price applicable to your Investor Warrant ($0.65 x number of shares to be exercised) by check or by wire transfer pursuant to the wire transfer instructions set forth below.

The Election
to Exercise Warrants Investor Warrants, Accredited Investor Questionnaire along with the exercise price must be received at the
address below, on or before October 30, 2014, but may be extended by the Company in its sole discretion.

 

	 	 	 	 
	
        ADDRESS FOR EXECTUED DOCUMENTS:

         

         

         

         

         

         
	 	
        DelMar Pharmaceuticals, Inc.

        Suite 720 -- 999 West Broadway

        Vancouver, British Columbia CANADA V5Z1K5

        Attn: Corporate Secretary

        Tel. No. (604) 629-5989

        Fax No. (604) 608-5685

         
	 
	 	 	 	 
	CHECKS PAYABLE TO:	
         

         
	 	 
	 	 	 
	 	 	 	 
	
        WIRE TRANSFER

        INSTRUCTIONS FOR

        EXERCISE OF

        WARRANTS:
	 	
         

         
	 
	 	 	 

Delivery to an
address other than as set forth above will not constitute a valid delivery.

    	5

    	 

    

 

ACCREDITED
INVESTOR QUESTIONNAIRE

The undersigned
understands that the purpose of this Questionnaire is to permit DelMar Pharmaceuticals, Inc. (“DelMar ”) to
determine whether the undersigned is an “accredited investor” as such term is defined in Rule 501(a) promulgated under
the Securities Act of 1933, as amended (the “ Act ”). The undersigned represents to you that (i) the information
contained herein is complete and accurate and may be relied upon by DelMar, and (ii) the undersigned will notify DelMar immediately
of any change in any of such information.

All information
furnished is for the sole use of DelMar and its counsel and will be held in confidence by DelMar and its counsel, except that this
Questionnaire may be furnished to such parties as DelMar deems desirable to establish compliance with federal or state securities
laws.

A. For
Individuals:

The undersigned individual is an “Accredited
Investor” for one or more of the following reasons (check all that apply):

 ̈
The undersigned is an individual (not a partnership, corporation,
etc.) whose individual net worth, or joint net worth with his or her spouse, presently exceeds $1,000,000. For purposes of the
foregoing, “net worth” shall be deemed to include all of your assets, liquid or illiquid (including such items as furnishings,
automobile and restricted securities, but excluding the value of your primary residence) minus any liabilities (including such
items as loans and other debts and liabilities, but excluding any mortgage on your primary residence to the extent that it does
not exceed the fair market value of such residence).

 ̈
The undersigned is an individual (not a partnership, corporation, etc.) who had (i) an individual income in excess of $200,000
or (ii) joint income together with their spouse in excess of $300,000, in each of the two most recent years and reasonably
expect to reach the same income level in the current year. For purposes of the foregoing, “income” is not limited to
“adjusted gross income” as that term is defined for federal income tax purposes, but rather includes certain items
of income which are deducted in computing “adjusted gross income”. For investors who are salaried employees, the gross
salary of such investor, minus any significant expenses personally incurred by such investor in connection with earning the salary,
plus any income from any other source including unearned income, is a fair measure of “income” for purposes of this
question. For investors who are self-employed, “income” is generally construed to mean total revenues received during
the calendar year minus significant expenses incurred in connection with earning such revenues.

 

 

		 ̈	The undersigned is a director, executive
officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general
partner of a general partner of that issuer.

 

		 ̈	The undersigned individual is not an “Accredited Investor”
because none of the above apply.

 

    	6

    	 

    

B. For Entities:

The undersigned is an “Accredited Investor”
because the undersigned falls within at least one of the following categories (Check all appropriate lines):

 

 ̈
(i) a bank as defined in Section 3(a)(2) of the Securities
Act of 1933, as amended (the “Securities Act”) or a savings and loan association or other institution as defined in
Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity;

 

		 ̈	(ii) a broker-dealer registered pursuant to Section 15 of the Securities
Exchange Act of 1934, as amended;

		 ̈	(iii) an insurance company as defined in Section 2(a)(13) of the Act;

		 ̈	(iv) an investment company registered
under the Investment Company Act of 1940, as amended (the “Investment Company Act”) or a business development company
as defined in Section 2(a)(48) of the Investment Act;

		 ̈	(v) a Small Business Investment Company
licensed by the U.S. Small Business Investment Act of 1958, as amended;

		 ̈	(vi) a plan established and maintained
by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit
of its employees, where such plan has total assets in excess of $5,000,000;

		 ̈	(vii) an employee benefit plan within
the meaning of Title I of the Employee Retirement Income Security Act of 1974, as amended (the “Employee Act”), where
the investment decision is made by a plan fiduciary, as defined in Section 3(21) of the Employee Act, which is either a bank, savings
and loan association, insurance company, or registered investment adviser, or an employee benefit plan that has total assets in
excess of $5,000,000 or a self-directed plan the investment decisions of which are made solely by persons that are accredited investors.

		 ̈	(viii) a private business development
company, as defined in Section 202(a)(22) of the Investment Advisers Act of 1940 as amended;

		 ̈	(ix) an organization described in Section
501(c)(3) of the Internal Revenue Code, a corporation, a Massachusetts or similar business trust, or a partnership, not formed
for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;

		 ̈	(x) a trust, with total assets in excess
of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a “sophisticated”
person, who has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and
risks of the prospective investment;

		 ̈	(xi) an entity in which all of the equity investors are persons or
entities described above.
	 	☐	The undersigned is an entity all the equity owners of which are “accredited
investors” within one or more of the above categories. If relying upon this Category alone, each equity owner must complete
a separate copy of this Questionnaire. (Describe the entity below).
	 	☐	The undersigned entity is not an “Accredited Investor”
because none of the above apply.
	 	 	 

 

The foregoing representations are true
and accurate as of the date hereof.

 

	 	 	 
	 	 
	Dated: October 31, 2014	 	
 

	 	 	Name of Investor
	 	 
	 	 	
 

	 	 	Signature
	 	 
	 	 	
 

	 	 	Printed Name
	 	 
	 	 	
 

	 	 	Title (if applicable)
	 	 
	 	 	
 

	 	 	Name of joint investor or other person whose signature is required
	 	 
	 	 	
 

	 	 	Signature
	 	 
	 	 	
 

	 	 	Title (if applicable)

 

 

7Exhibit 10.2

AMENDMENT NO. 1 TO WARRANT TO
PURCHASE COMMON STOCK

 

This Amendment No.
1 to Warrant to Purchase Common Stock (this “Amendment”), dated as of October 31, 2014, is entered into
by and among DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and ________________________________
(the “Holder”) who hereby confirms the ownership of _______ warrants which have been properly issued or transferred
to the Holder in accordance with the terms of the Warrant.

WITNESSETH:

WHEREAS, on January
24, 2013, the Company issued a warrant to purchase common stock to the Holder (the “Warrant”);

WHEREAS, the Company
and the Holder desire to amend the Warrant as more particularly set forth below;

NOW, THEREFORE,
in consideration of the covenants and mutual promises contained herein and other good and valuable consideration, the receipt and
legal sufficiency of which are hereby acknowledged and intending to be legally bound hereby, the parties agree as follows:

1.The following
sentence shall be added at the end of Section 1(a):

For the avoidance
of doubt, in the event the Company does not have an effective registration statement there is no circumstance that would require
the Company to net cash settle the Warrants.

2.Section 1(b)(iv)
of the Warrant shall be deleted in its entirety and replaced by the following which shall be inserted in lieu thereof:

Reserved.

3.Section 4
of the Warrant shall be deleted in its entirety and replaced by the following which shall be inserted in lieu thereof:

Reserved.

4.Except as
modified herein, the terms of the Warrant shall remain in full force and effect.

5.This Amendment
may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and shall be binding
upon all parties, their successors and assigns, and all of which taken together shall constitute one and the same Amendment. A
signature delivered by facsimile shall constitute an original.

[Signature Page Follows]

 

    	 

    	 

    

[SIGNATURE PAGE TO AMENDMENT TO WARRANT
TO PURCHASE COMMON STOCK]

IN WITNESS WHEREOF,
the parties hereto have executed this Amendment as of the date set forth above.

DELMAR PHARMACEUTICALS, INC.

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

HOLDER:

_____________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]